Duval/CIBMTR Score for Acute Myelogenous Leukemia (AML) Survival
Predicts overall survival in AML patients with relapsed/refractory disease undergoing myeloablative transplant.
Use in patients with relapsed or refractory active AML for whom hematopoietic stem cell transplant (HSCT) is being considered. Do not use in patients with chronic myelogenous leukemia (CML) in blast crisis.
Advice
High-risk patients with 3-year overall survival (OS) of 6% should be counseled and preferably referred for relapse-mitigation clinical trials.
Management
HSCT should be considered in patients with scores ≤2 in the context of other available therapies, given their predicted OS of 15-46%.
Critical Actions
Risk should be discussed with the patient.